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ABSTRACT 
Following a request by the European Commission the Scientific Panel on Food Additives and Nutrient 
Sources added to Food (ANS) was asked to conclude on the possible link between the ingestion of β-
carotene and cancer enhancement in heavy smokers. The safety of (synthetic) β-carotene [E 160a (ii)] 
has been evaluated previously by JECFA (1975) and by the SCF (2000a).  In 2000, the SCF concluded 
that there were insufficient data to set a precise figure for a Tolerable Upper Intake Level (UL) of β-
carotene (SCF, 2000b). Unexpectedly, two independent trials revealed that heavy smokers (at least 1 
package/day for 36 years on average) receiving long-term β-carotene (20 mg/day) supplementation or 
β-carotene (30 mg/day) + retinol (25 000 International Unit (IU) vitamin A) supplementation, showed 
increased rather than decreased incidences of lung cancer. A meta-analysis of randomized controlled 
trials (RCT) demonstrated absence of any protective effect associated with β-carotene supplementation 
with regard to cancer risk. Epidemiological studies reported no increased lung cancer incidence in 
heavy smokers at supplemental dose levels of β-carotene varying from 6 – 15 mg/day for about 5 up to 
7 years. The Panel concluded that exposure to β-carotene from its use as food additive and as food 
supplement at a level below 15 mg/day do not give rise to concerns about adverse health effects in the 
general population, including heavy smokers. 
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SUMMARY 
Following a request by the European Commission the Scientific Panel on Food Additives and Nutrient 
Sources added to Food (ANS) was asked to conclude on the possible link between the ingestion of β-
carotene and cancer enhancement in heavy smokers. 
The safety of (synthetic) β-carotene [E 160a (ii)] has been evaluated previously by JECFA (1975) en 
the SCF (2000a). In 2000, the SCF concluded that there were insufficient data to set a precise figure 
for a Tolerable Upper Intake Level (UL) of β-carotene (SCF, 2000b). 
In the past, high serum β-carotene levels have been associated with a decrease in incidence of cancer, 
including lung cancer, in humans (Mayne, 1996; Ziegler et al., 1996). However, the ATBC study and 
CARET trials (ATBC Study group, 1994; Omenn et al., 1996a; 1996b; Omenn, 1998) unexpectedly 
revealed that heavy smokers (at least 1 package/day for 36 years on average) receiving long-term β-
carotene (20 mg/day) supplementation (ATBC) or β-carotene (30 mg/day) + retinol (25 000 
International Unit (IU) vitamin A) supplementation (CARET), showed increased rather than decreased 
incidences of lung cancer.  
In 2010, Druesne-Pecollo et al. performed a meta-analysis of randomized controlled trials (RCT) 
investigating β-carotene supplementation and cancer risk. They found absence of any protective effect 
associated with β-carotene supplementation with regard to primary cancer risk. However, their 
analyses indicated an increased risk of lung cancers in individuals supplemented with β-carotene at 
dose levels equal to or greater than 20 mg/day as well as in smokers and asbestos workers 
supplemented with β-carotene. A statistically significant interaction was found between β-carotene 
intake and smoking status.  
Epidemiological studies reported no increased lung cancer incidence in heavy smokers at 
supplemental dose levels of β-carotene varying from 6 – 15 mg/day for about 5 up to 7 years 
(Druesne-Pecollo et al., 2010). 
The Panel concluded that exposure to β-carotene from its use as food additive and as food supplement 
at a level below 15 mg/day do not give rise to concerns about adverse health effects in the general 
population, including heavy smokers. 
 Statement of the safety of β-carotene use in heavy smokers 
 
EFSA Journal 2012;10(12):2953  3
TABLE OF CONTENTS 
Abstract .................................................................................................................................................... 1 
Summary .................................................................................................................................................. 2 
Table of contents ...................................................................................................................................... 3 
Background as provided by European Commission ................................................................................ 4 
Terms of reference as provided by European Commission  ...................................................................... 4 
Evaluation ................................................................................................................................................. 5 
Conclusions .............................................................................................................................................. 5 
Documentation provided to EFSA ........................................................................................................... 6 
References ................................................................................................................................................ 6 
Glossary/Abbreviations ............................................................................................................................ 7 Statement of the safety of β-carotene use in heavy smokers 
 
EFSA Journal 2012;10(12):2953  4
BACKGROUND AS PROVIDED BY EUROPEAN COMMISSION 
On 14
th of March 2012 the ANS Panel published the scientific opinion on the re-evaluation of mixed 
carotenes (E 160a (i) and β-carotene (E 160a (ii) as a food additive. However, in the view of the 
European Commission, this opinion did not specifically conclude on the possible link between the 
ingestion of β-carotene and cancer enhancement in heavy smokers, nor does it provide the 
Commission with an upper safe level for β-carotene for this category of the population, as requested in 
the initial mandate of 27
th of February 2009. 
The European Food Safety Authority (EFSA) has informed the Scientific Panel on Food Additives and 
Nutrient Sources added to food (ANS) that on 25
th of June 2012, the European Commission has 
requested EFSA to give further guidance on the basis of the previous mandate on safe use of β-
carotene sent to EFSA (ref: EFSA-Q-2009-00830); i.e. to review the existing data on the possible link 
between β-carotene and cancer enhancement in heavy smokers, to advise the Commission on an upper 
safe level of intake (UL) of β-carotene in heavy smokers, and if not possible to set an UL, to provide 
advice on a daily intake of β-carotene that does not give rise to concerns about adverse health effects 
in heavy smokers. 
TERMS OF REFERENCE AS PROVIDED BY EUROPEAN COMMISSION 
The ANS will produce a Panel Statement on the above request for the European Commission to 
provide advice on a daily intake of β-carotene that does not give rise to concerns about adverse health 
effects in heavy smokers. 
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EVALUATION 
Following a request by the European Commission the Scientific Panel on Food Additives and Nutrient 
Sources added to Food (ANS) was asked to conclude on the possible link between the ingestion of β-
carotene and cancer enhancement in heavy smokers. 
The safety of (synthetic) β-carotene [E 160a (ii)] has been evaluated previously by Joint FAO/WHO 
Expert Committee on Food Additives JECFA (1975) and by the Scientific Committee for Food (SCF) 
(2000a). In 2000, the SCF concluded that there was insufficient data to set a precise figure for a 
Tolerable Upper Intake Level (UL) of β-carotene (SCF, 2000b). 
In the past, high serum β-carotene levels have been associated with a decrease in incidence of cancer, 
including lung cancer, in humans (Mayne, 1996; Ziegler et al., 1996). However, the ATBC study and 
CARET trials (ATBC Study group, 1994; Omenn et al., 1996a; 1996b; Omenn, 1998) unexpectedly 
revealed that heavy smokers (at least 1 package/day for 36 years on average) receiving long-term β-
carotene (20 mg/day) supplementation (ATBC) or β-carotene (30 mg/day) + retinol (25 000 
International Unit (IU) vitamin A) supplementation (CARET), showed increased rather than decreased 
incidences of lung cancer.  
In 2009, DSM conducted an extensive review of the scientific literature, published since 2000 on the 
relationship between β-carotene supplementation and cancer risk. The negative effects observed in 
heavy smokers in the ATBC and CARET studies were not seen in any other intervention study. 
Therefore, the authors concluded that the increased lung cancer incidence in β-carotene supplemented 
smokers has been demonstrated to be specific to individuals who chronically smoke more than 20 
cigarettes per day. 
Druesne-Pecollo et al. (2010) performed a systematic review and meta-analysis of randomized 
controlled trials (RCT) investigating β-carotene supplementation and cancer risk. The meta-analysis 
from these studies, including 180 702 subjects and 1852 cases of lung cancer, gave a significant 
overall increased Relative Risk (RR) of 1.13 (95% Confidence Interval (CI), 1.04 – 1.24) in subjects 
supplemented with β-carotene compared to those receiving placebo. Compared to corresponding 
placebo groups, the risk of lung cancer was significantly increased in subjects supplemented either 
with β-carotene in combination with other antioxidants (RR of 1.16; 95% CI, 1.04 – 1.29) or with 
doses of 20 mg/day of β-carotene and above (RR, 1.16; 95% CI, 1.06 – 1.27). Significantly increased 
overall RR were also found for subjects supplemented with β-carotene in populations exclusively 
composed of smokers or asbestos workers (RR, 1.20; 95% CI, 1.07 – 1.34) as well as in populations 
with a majority of men (RR, 1.14; 95% CI, 1.04 – 1.25) compared to the control groups. No significant 
effect of β-carotene supplementation was observed in the other subgroup analyses. 
The authors found absence of any protective effect associated with β-carotene supplementation with 
regard to primary cancer risk. However, their analyses indicated an increased risk of lung cancers in 
individuals supplemented with β-carotene at dose levels equal to or greater than 20 mg/day as well as 
in smokers and asbestos workers supplemented with β-carotene. A statistically significant interaction 
was found between β-carotene intake and smoking status.  
Epidemiological studies reported no increased lung cancer incidence in heavy smokers at 
supplemental dose levels of β-carotene varying from 6 – 15 mg/day for about 5 up to 7 years 
(Druesne-Pecollo et al., 2010). 
CONCLUSIONS 
The Panel concluded that exposure to beta-carotene from its use as food additive and as food 
supplement at a level below 15 mg/day do not give rise to concerns about adverse health effects in the 
general population. The Panel noted that as no sensitive groups were identified from the available 
evidence at this exposure, the term general population covers all groups including heavy smokers. Statement of the safety of β-carotene use in heavy smokers 
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GLOSSARY/ABBREVIATIONS 
ANS  Scientific Panel on Food Additives and Nutrient Sources added to Food 
CARET  β-Carotene and Retinol Efficacy Trial  
CI  Confidence Interval  
EFSA  European Food Safety Authority 
IU International  Unit   
JECFA  Joint FAO/WHO Expert Committee on Food Additives  
UL  Tolerable Upper Intake Level  
RR  Relative Risk  
RCT  Randomized Controlled Trials  
SCF  Scientific Committee for Food  
 